Another day, another early FDA nod. Global Blood Therapeutics has its first drug approval, and it’s one that’ll bring a “paradigm shift” in how patients with sickle cell disease are treated, execs say. Monday, the FDA approved Oxbryta, formerly known as voxelotor, to treat sickle cell disease patients aged 12 and older.
